DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM June 26, 2018 • 6:00 AM EDT
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors June 25, 2018 • 6:00 AM EDT
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results May 17, 2018 • 5:30 AM EDT
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM April 17, 2018 • 2:00 PM EDT
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research April 16, 2018 • 9:00 AM EDT
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results February 14, 2018 • 5:39 PM EST
DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma December 26, 2017 • 5:30 AM EST
DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting November 21, 2017 • 3:06 PM EST
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results November 13, 2017 • 6:14 PM EST